Solutions - Page 3

The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company’s plan to infuse $100 billion into its American operations over

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner speaks with Atradius’ Brady McKinney about how tariff pressures drove a 2025 manufacturing surge in pharma and why production is expected

Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply source for shikimic acid, a key starting material used in the production

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.

Stada will invest more than 85 million euros (around $101 million) to build a new production facility in Saudi Arabia, which will ultimately serve as a supply hub for the broader Middle

The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient Actinium-225 (Ac-225) used to